{
    "nct_id": "NCT05605899",
    "official_title": "An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)",
    "inclusion_criteria": "* Histologically confirmed large B cell lymphoma (LBCL) based on 2016 World Health Organization (WHO) classification by local pathology lab assessment, including of the following:\n\n  * Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)\n  * High-grade B-cell lymphoma (HGBL)\n* Note: Transformed DLBCL from follicular lymphoma or from marginal zone lymphoma is eligible if no prior treatment with anthracycline-containing regimen.\n* High-risk disease defined as an International Prognostic Index (IPI) score of 4 or 5 at initial diagnosis.\n* Have received only 1 cycle of rituximab plus chemotherapy (R-chemotherapy).\n* Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.\n* Females of childbearing potential must have a negative serum or urine pregnancy test.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* The following WHO 2016 subcategories by local assessment:\n\n  * T-cell/histiocyte-rich LBCL\n  * Primary DLBCL of the central nervous system (CNS)\n  * Primary mediastinal (thymic) LBCL\n  * B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma\n  * Burkitt lymphoma\n  * History of Richter's transformation of chronic lymphocytic leukemia\n* Presence of detectable cerebrospinal fluid (CSF)-malignant cells, brain metastases, or a history of CNS involvement of lymphoma.\n* Presence of cardiac lymphoma involvement.\n* Any prior treatment for LBCL other than the 1 cycle of R-chemotherapy.\n* History of severe immediate hypersensitivity reaction to any of the agents used in this study.\n* Presence of CNS disorder. History of stroke, transient ischemic attack, or posterior reversible encephalopathy syndrome (PRES) within 12 months prior to enrollment.\n* History of acute or chronic active hepatitis B or C infection.\n* Positive for human immunodeficiency virus (HIV) unless taking appropriate anti-HIV medications, with an undetectable viral load by PCR and with a cluster of differentiation 4 (CD4) count > 200 cells/uL.\n* Medical conditions or residual toxicities from prior therapies likely to interfere with assessment of safety or efficacy of study treatment. Please refer to protocol for further details.\n* History of clinically significant cardiac disease within 12 months before enrollment.\n* History of any medical condition requiring maintenance systemic immunosuppression/systemic disease modifying agents within the last 2 years.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}